Elevated expression of ARL4C in immune cells, which is correlated with the activation of the cancer immune response, has been associated with unfavorable prognoses in several cancers, including bladder urothelial carcinoma, colon adenocarcinoma, kidney renal papillary cell carcinoma, lower-grade glioma, and uterine corpus endometrial carcinoma (45). Here, ARL4C is linked to uterine corpus endometrial carcinoma.